tbuckley/cabot-search huggingface dataset:
Persistent cytomegalovirus in liver allografts with chronic rejection
Authors: I. Lautenschlager, K. Höckerstedt, H. Jalanko, R. Loginov, K. Salmela, E. Taskinen, J. Ahonen
Journal: Hepatology (1997)

Cytomegalovirus (CMV) infection is one of the suggested risk factors for chronic allograft rejection. Clinical and experimental studies have shown that CMV is somehow implicated in rejection mechanisms and in the generation of graft arteriosclerosis, characteristic of chronic rejection. In liver transplantation, there is also evidence of an association between CMV and vanishing bile duct–syndrome (VBDS), which is characteristic of chronic liver allograft rejection. In this study, the role of posttransplant CMV infection and of acute rejection in the patients with irreversible, histologically confirmed chronic liver rejection with VBDS and vasculopathy was analyzed. Ten of 200 (5%) consecutive liver transplants were lost due to chronic rejection, from between 5 and 28 months from transplantation. In these 10 patients, acute rejections were frequent, and nine of ten patients had at least one episode of rejection early after transplantation. All patients (10 of 10) had a history of CMV infection usually following acute rejection. To investigate the role of CMV in chronic rejection, nine available removed grafts were examined for the presence of the CMV genome by DNA–hybridization in situ using a biotinylated CMV–DNA probe. Persistent CMV–DNA was found in all of those available grafts with chronic rejection. CMV–DNA was strongly expressed in the remaining bile ducts and moderately expressed in the endothelial cells of the vascular structures, the CMV positivity of hepatocytes varied from graft to graft. Thus, persistent CMV genome was found in those structures that are the major targets of the chronic rejection process in the liver. These findings support the previous suggestion of an association between CMV and chronic allograft rejection.
The Frequency of Genetic Anomalies According to Clonal Plasma Cells' Phenotype in Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)
Authors: Andrei Garifullin, Irina Martynkevich, Sergei Voloshin, Alexei Kuvshinov, Ludmila Martynenko, Elizaveta Kleina, Kudrat Abdulkadyrov
Journal: Blood (2015)
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Authors: Christian Scharenberg, Valentina Giai, Andrea Pellagatti, Leonie Saft, Goran Karlsson, Monika Jansson, Lalla Forsblom, Martin Jadersten, Stefan Karlsson, Jacqueline Boultwood, Eva Hellstrom-Lindberg
Journal: Blood (2011)
Stroke Diagnosis and Treatment in the Emergency Department
Authors: Jason L. Siegel, Michael A. Pizzi, William David Freeman
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
IFN-β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-α in PBMCs of Adult T-cell Leukemia/Lymphoma patients
Authors: T Dierckx, R Khouri, S M Menezes, D Decanine, L Farre, A Bittencourt, A M Vandamme, J Van Weyenbergh
Journal: Blood Cancer Journal (2017)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, to AB, JVW and AMV “PVE”), PRONEX (CNPq-FAPESB to AB and JVW and LF), FWO (Grant: ZKC1280-00-W10 and G0D6817N to AMV)
Enhancing Effect of Collagen Receptor Polymorphisms on In Vitro Platelet Reactivity to Aspirin in Healthy Subjects.
Authors: Miho Ushida, Yumiko Matsubara, Shinichi Takahashi, Hiroaki Ishihara, Toshiro Shibano, Gentaro Watanabe, Yasuo Ikeda, Mitsuru Murata
Journal: Blood (2006)
High-risk human papillomavirus in anal squamous cell carcinoma: a ‘conservative’ leading role
Authors: P.S. Ravenda, M.G. Zampino, E. Guerini-Rocco, S. Chiocca, V. Dell’Acqua, C. Trovato, R. Biffi, D. Ribero, F. Spada, C.A. Cella, N. Fazio
Journal: Annals of Oncology (2017)
Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,
Authors: Donna E. Reece, Giovanni Piza Rodriguez, David Szwajcer, Leonard A Minuk, Mariela Pantoja, Andrew Belch, Chaim Shustik, Julie Stakiw, Darrell J. White, Christine Chen, Vishal Kukreti, Rodger E. Tiedemann, Michael Sebag, Gayle Jenkins, Nizar J Bahlis, Lisa W Le, Suzanne Trudel
Journal: Blood (2011)
Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders
Authors: Juliana Perez Botero, Laynalee K Cardel, Aneel A. Ashrani, John A. Heit, Rong He, C Christopher Hook, Robert D McBane, Animesh Pardanani, Deepti M. Warad, Waldemar E Wysokinski, Vilmarie Rodriguez, William L. Nichols, Rajiv K. Pruthi, Dong Chen, Mrinal M Patnaik
Journal: Blood (2015)
Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome
Authors: Weiyun Ai, Chen-Yen Yang, Razan Faraj, Taha Rakhshandhroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick
Journal: Blood (2015)
Stat3 Activation in Donor CD4 T-Cells Is Critical for Acute Gvhd
Authors: Katsutoshi Ozaki, Haruko Matsu, Keiko Hatanaka, Akiko Meguro, Iekuni Oh, Raine Tatara, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa
Journal: Blood (2011)
The structure-activity relationship (SAR) of and novel molecular mechanisms for ginsenosides as anticancer agents
Authors: Wei Wang, Haiyan Chen, Yuqing Zhao, Hui Wang, Ruiwen Zhang
Journal: Cancer Research (2006)

1921  Ginseng has been used for thousands of years in Asian countries for its wide spectrum of health effects, and is known for its tonic, immunomodulatory, adaptogenic and anti-aging activities. The use of ginseng and related products in cancer prevention and treatment also has been explored for many years in Western countries. Many of its medicinal effects and pharmacological actions are attributed to ginsenosides that include more than twenty family members with varying biological activities. Multiple mechanisms of action for ginsenosides have been suggested, including anti-inflammatory and antioxidant effects, induction of apoptosis, regulation of gene expression and modulation of cell proliferation. However, the underlying molecular mechanisms and the SAR of ginsenosides are not fully understood. This study was undertaken to investigate the SAR of selected ginsenosides for their anti-cancer effects. Among 12 ginsenosides tested, two newly identified compounds, 25-OH-PPD and 25-OCH3-PPD, were shown to be most active based on their effects on cell viability, apoptosis, cell cycle distribution, and cell proliferation in human breast cancer MCF7 (p53wt/wt) and MDA-MB-468 (p53mt/mt) cells and prostate cancer LNCaP (p53wt/wt) and PC3 (p53null) cells. For example, 25-OCH3-PPD had the most potent anti-cancer activities, having IC50 values of 13.5, 18.2, 12.0 and 5.6 microM in MCF7, MDA-MB-468, LNCaP, and PC3 cells, respectively. In contrast, other compounds had 10-100-fold lower activities. In a dose- and structure-dependent manner, effective ginsenosides arrested cancer cells in the G1 phase. This arrest was accompanied by down-regulation of the MDM2 oncogene and activation of tumor suppressors such as p53 and p21WAF1/CIP1. In conclusion, several ginsenosides, especially 25-OH-PPD and 25-OCH3-PPD, exert their anticancer activity through inducing apoptosis and G1 arrest and inhibiting proliferation in cancer cells, regardless of p53 status. Their down-regulation of the MDM2 oncogene has not been previously reported, and is a novel molecular mechanism for their anticancer effects. These results provide a basis for further development of ginsenoside analogs as novel agents in cancer prevention and therapy.
A retrospective study of performance status in oncology patients at diagnosis and over the first year in routine clinical practice.
Authors: C. J. Paoli, B. A. Bach, K. T. Tsai, B. Wong
Journal: Journal of Clinical Oncology (2011)

e16521 Background: Measurements of performance status with the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score are widely used to stratify subjects at clinical trial entry are correlated with treatment outcome; however, ECOG-PS is rarely tracked over time. Longitudinal ECOG-PS measurement between tumor types may provide important data for patient management in community settings, therefore this study examined the distribution of ECOG-PS by tumor type from diagnosis through the subsequent 12 months in community oncology clinics. Methods: We retrieved ECOG-PS scores (0=best, 5=dead) from the electronic medical records (EMRs) of 47 general oncology/hematology clinics across the US. Patients included had ICD-9 diagnostic codes for breast, lymphoma, prostate, colorectal and lung cancers and ECOG-PS score recorded within 14 days of diagnosis date. All patients with at least one ECOG-PS measurement were included in the study. Descriptive statistics of ECOG-PS at diagnosis and by longitudinal month were analyzed as means with standard deviation. ECOG-PS at diagnosis was compared between tumor types using Wilcoxon rank sum test. Results: A total of 28,754 cancer patients were identified from the EMR: 10,489 breast, 4,072 lymphoma, 2,769 prostate, 4,636 colorectal, and 7,252 lung. At baseline, mean (SD) ECOG-PS scores were: breast, 0.56 (0.79); lymphoma, 0.67 (0.83); prostate, 0.75 (0.91); colorectal, 0.85 (0.88); and lung, 1.17 (0.95). Mean scores within tumor types remained stable over the 12 following months. Proportion of patients with ECOG-PS <2 at diagnosis was 89%, 87%, 82%, 81% and 68% for each tumor respectively. Pairwise comparisons of baseline ECOG-PS between tumor types were all statistically significant, p<0.05. Conclusions: This study provides a description of a national sampling of community oncology patients’ performance status. Although significant differences between tumor types were found, the persistence of relatively good ECOG-PS in all 5 tumor types over time contrasts with the poor status of patients in clinical trials. These findings offer oncology providers, data upon which resource planning can be based.
Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.
Authors: Parameswaran N Hari, A. John Barrett, Smriti Shrestha, Gisela Tunes da Silva, Mei-Jie Zhang, Angela Dispenzieri, Gustavo A. Milone, Sagar Lonial, Olle Ringden
Journal: Blood (2009)
Peripheral Blood CD34+ Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Authors: Maxim Norkin, Amy Meacham, Mai H Ta, Neil Benson, Steven Goldstein, Emma Rosenau, Jack W. Hsu, Christopher R. Cogle, John W Hiemenz, Randy A. Brown, John R. Wingard
Journal: Blood (2012)
The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience.
Authors: Nicholas N. Tadros, Paige E. Farris, Jackilen Shannon, Tomasz M. Beer, Mark Garzotto
Journal: Journal of Clinical Oncology (2012)

87 Background: The safety of routine prostate biopsies has recently been called into question, citing increasing rates of complications compared to historical data. We examined our experience with prostate biopsies done as a component of multiple clinical research trials. Methods: The safety of routine prostate biopsies has recently been called into question, citing increasing rates of complications compared to historical data. We examined our experience with prostate biopsies done as a component of multiple clinical research trials. Results: 141 charts had adequate documentation. A mean of 12 +/- 4 cores were obtained during the procedures (8-26). Of these patients, 136 of the 141 had no adverse events during or after their biopsies. Of the five adverse events, there were three (2.2%) minor and two (1.4%) major complications. The minor complication group consisted of three patients with mild, but prolonged hematuria (12-14 days). Of the two major complications, one patient had hematospermia for 28 days and the second patient was diagnosed with prostatitis 18 days after biopsy and required multiple antibiotics. No patient required any further intentions or hospitalizations. There was no correlation between complication rate and study type (p=0.662) or treatment setting (p=0.411). Overall, 96.5% of patients undergoing prostate biopsies for research purposes had no adverse events or complications related to the procedure. Conclusions: Research related prostate biopsy procedures can be performed in a diverse range of treatment settings and do not incur any increased risk versus clinical biopsies.
A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression
Authors: Tzu-Chieh Ho, Craig T Jordan, Mark W. LaMere, John M. Ashton, Kristen O'Dwyer, Jason H. Mendler, Jane L. Liesveld, Eunice S. Wang, Monica L. Guzman, Laura M. Calvi, Michael W. Becker
Journal: Blood (2015)
GP leaders in Northern Ireland to begin collecting resignation letters from practices
Authors: Gareth Iacobucci
Journal: BMJ (2017)

GPs in Northern Ireland have moved a step closer to leaving the NHS after the BMA voted to allow general practice leaders in Northern Ireland to begin collecting undated resignations from practices.

The association’s Northern Ireland General Practitioners Committee voted on Wednesday 25 January to proceed with the action after the province’s government failed to commit to an urgent financial rescue package for general practice.

GPs in Northern Ireland had warned that they may be forced to leave the NHS after the rescue package was derailed by the collapse of the assembly government.1

Tom Black, chair of the GP committee, told The BMJ that it would action the resignation letters when …
Bone Density in Thalassemia Major Improves in Longterm Transplant Survivors.
Authors: Ting Fan Leung, Chi Kong Li, Christopher W.K. Lam, Yvonne Chu, Matthew M.K. Shing, Chung Yi Li, Iris H.S. Chan, Ki Wai Chik, Vincent Lee, Patrick M.P. Yuen
Journal: Blood (2004)
Continuous glucose monitoring can benefit patients with type 1 diabetes
Authors: Jacqui Wise
Journal: BMJ (2017)

Continuous glucose monitoring can improve glycaemic control in patients with type 1 diabetes who use insulin injections, two studies published in JAMA have found.12

This consists of a sensor under the skin with a transmitter attached that reports glucose levels continuously to the patient on a handheld monitor. Most patients whose continuous glucose monitoring has been compared with self monitored blood glucose have used insulin pumps, whereas the two new studies were carried out in patients with type 1 diabetes who injected insulin.

The DIAMOND study included 158 …
Primary Pancreatic Anaplastic Large Cell Lymphoma, ALK-: A Care Report.
Authors: Christos G. Savopoulos Lecturer, Niki E. Tsesmeli, Georgia D. Kaiafa, Anestis Th. Zantidis, Matheos T. Bobos, Apostolos I. Hatzitolios, Athanasios Papadopoulos, Ioannis S. Kostopoulos
Journal: Blood (2005)
Results of PETHEMA LAL-BR-01 Protocol for Low-Risk (LR) Acute Lymphoblastic Leukemia (ALL) In Children
Authors: Josep-Maria Ribera, Albert Oriol, Mireia Morgades, Pilar Bastida, Olga Garcia, Alvaro Lasaletta, Jose-Luis Fuster, Elvira Gonzalez-Valentin, Inmaculada Soto, Ana Carbone, Antonio Molines, Izaskun Egurbide, Andres Llorente, Esmeralda Benitez, Luis Madero, Jose Sanchez de Toledo
Journal: Blood (2010)
Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.
Authors: Shingen Nakamura, Masahiro Abe, Qu Cui, Ayako Nakano, Asuka Oda, Hiroe Amou, Akishige Ikegame, Takeshi Harada, Masahiro Hiasa, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Shuji Ozaki, Toshio Matsumoto
Journal: Blood (2009)
The Suppressive Effect of Bone Marrow Mesenchymal Stem Cells on T Cell Activation, Is Deficient in Patients with Severe Aplastic Anemia.
Authors: Andrea Bacigalupo, Marisa Valle, Marina Podesta’, Anna Pitto, Elena Zocchi, Antonio De Flora, Sarah Pozzi, Franca Vassallo, Silvia Lucchetti, Osvaldo Figari, Francesco Frassoni, Giovanna Piaggio
Journal: Blood (2004)
Screening for Gestational Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement
Journal: Annals of Internal Medicine (2014)

Description: Update of 2003 U. S. Preventive Services Task Force (USPSTF) recommendation about screening for gestational diabetes. Methods: The USPSTF weighed the evidence on maternal and neonatal benefits (reduction in preeclampsia, mortality, brachial plexus injury, clavicular fractures, admission to the neonatal intensive care unit for serious illnesses) and harms (physical and psychological harms) of screening for gestational diabetes identified for their 2003 recommendation and the accompanying systematic review of articles published since the 2003 review for screening after 24 weeks' gestation. Additional searches were performed for evidence published from 1966 to 1999 on screening before 24 weeks. Recommendation: Current evidence is insufficient to assess the balance of benefits and harms of screening for gestational diabetes mellitus, either before or after 24 weeks' gestation. (I statement.)
The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease
Authors: Charlotte R. Hedin, Christopher J. van der Gast, Andrew J. Stagg, James O. Lindsay, Kevin Whelan
Journal: Gut Microbes (2017)

Siblings of patients with Crohn's disease (CD) have elevated risk of developing CD and display aspects of disease phenotype, including faecal dysbiosis. In our recent article we have used 16S rRNA gene targeted high-throughput sequencing to comprehensively characterize the mucosal microbiota in healthy siblings of CD patients, and determine the influence of genotypic and phenotypic factors on the gut microbiota (dysbiosis). We have demonstrated that the core microbiota of both patients with CD and healthy siblings is significantly less diverse than controls. Faecalibacterium prausnitzii contributed most to core metacommunity dissimilarity between both patients and controls and between siblings and controls. Phenotype/genotype markers of CD risk significantly influenced microbiota variation between and within groups, of which genotype had the largest effect. Individuals with elevated CD-risk display mucosal dysbiosis characterized by reduced diversity of core microbiota and lower abundance of F. prausnitzii. The presence of this dysbiosis in healthy people at-risk of CD implicates microbiological processes in CD pathogenesis.
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Authors: Athalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde, Maxwell Coll, Jacqueline Fung, Mary Paty Bryant, Leandra Cole, Kristen Palmer, Poorvi Somaiya, Rebecca Karp Leaf, Myrna Nahas, Arie Apel, Salvia Jain, Malgorzata McMasters, Lourdes Mendez, James Levine, Robin Joyce, Jon Arnason, Pier Paolo Pandolfi, Donald Kufe, Jacalyn Rosenblatt, David Avigan
Journal: Blood (2017)
MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD)
Authors: Nina C. Zitzer, Patricia A. Taylor, Apollinaire Ngankeu, Yvonne A. Efebera, Steven M. Devine, Bruce R. Blazar, Ramiro Garzon, Parvathi Ranganathan
Journal: Blood (2015)
Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide
Authors: Herve Avet Loiseau, Jean Soulier, Jean-Paul Fermand, Thierry Facon, Michel Attal, Jean-Luc Harousseau, Karim Belhadj, Cyril Hulin, Laurent Garderet, Veronique Dorvaux, Philippe Moreau
Journal: Blood (2008)
Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.
Authors: Remy Gressin, Sylvie caulet Maugendre, Steven Le Gouill, Mario ojeda Uribe, Magda Alexis Vigier, Krimo Bouabdallah, Christiane Mounier, Olivier Tournilhac, Philippe Rodon, Abderrazak El Yamani, Laurent Sutton, Delphine Senecal, Bruno Lioure, David Assouline, Annie Le Mevel, Bruno Villemagne, Charles Dauriac, Martine Gardembas, Sophie Park, Thierry Lamy
Journal: Blood (2008)
Mesenchymal Stromal Cells Accelerate Hematopoietic Reconstitution and Mediate An IL6-Dependent Regeneration of the Intestinal Epithelium of Lethally Irradiated Mice.
Authors: Moira Francois, Elena Birman, Daniel L. Coutu, Kathy-Ann Forner, Jacques Galipeau
Journal: Blood (2010)
Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.
Authors: Issa F. Khouri, Rima M. Saliba, Partow Kebriaei, Carrie Ma, Cindy Ippoliti, Daniel R. Couriel, Marcus de Lima, Sergio Giralt, Muzaffar H. Qazilbash, James L. Gajewski, Richard E. Champlin
Journal: Blood (2004)
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
Authors: Richard Jackson, Eftychia-Eirini Psarelli, Sarah Berhane, Harun Khan, Philip Johnson
Journal: Journal of Clinical Oncology (2017)

Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. To address this, we undertook an individual patient data meta-analysis of three large prospective randomized trials in which sorafenib was the control arm. Methods Of a total of 3,256 patients, 1,643 (50%) who received sorafenib were available. The primary end point was overall survival (OS). A Bayesian hierarchical approach for individual patient data meta-analyses was applied using a piecewise exponential model. Results are presented in terms of hazard ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status. Results Hazard ratios show improved OS for sorafenib in patients who are both HBV negative and HCV positive (log [hazard ratio], −0.27; 95% CI, −0.46 to −0.06). Median unadjusted survival is 12.6 (11.15 to 13.8) months for sorafenib and 10.2 (8.88 to 12.2) months for “other” treatments in this subgroup. There was no evidence of improvement in OS for any other patient subgroups defined by HBV and HCV. Results were consistent across all trials with heterogeneity assessed using Cochran’s Q statistic. Conclusion There is consistent evidence that the effect of sorafenib on OS is dependent on patients’ hepatitis status. There is an improved OS for patients negative for HBV and positive for HCV when treated with sorafenib. There was no evidence of any improvement in OS attributable to sorafenib for patients positive for HBV and negative for HCV.